samedan logo
 
 
spacer
home > pmps > spring 2003 > child-resistant blister packs
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Child-Resistant Blister Packs

In recent years claims that non-reclosable flexible packaging for pharmaceutical solid dose products - in particular blisters - are not child safe have become more frequent. The Child Safety Packaging Group in the UK has been lobbying for a relative standard since 1995 and increased their activities following the lethal ingestion of 44 tablets containing ferrous-sulphate by a three year old boy - tablets that had allegedly been packed in blisters, although no evidence to prove this was produced.

Following a public debate it was decided that the UK would introduce a British standard and not wait for the Centre Européen de Normalisation (CEN) to present a European standard so that the MCA could revise its legislation.

The idea of child-resistant packaging was first introduced in the US by the Code of Federal Regulation in 1974. While the importance and benefits of legislation are widely accepted and regulation regarding potentially harmful household product is covered by EU Directives, only four member states have legislation covering pharmaceuticals. Germany introduced DIN 55559 in 1980 with the Netherlands following closely behind. In Italy testing does not allow the involvement of children but accepts child-resistant packaging as soon as it has been recognised as being child-resistant in another EU member state.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tassilo Korab, Director, Head of the Business Unit Pharma Packaging at Teich


After studying Economics in Vienna, Tassilo Korab started his career as an International Sales Manager and has been in the packaging industry for more than 15 years. Now based at Teich in Austria, he is responsible for pharmaceutical packaging materials produced by Constantia Verpackungen AG, of which Teich is part.


spacer
Tassilo Korab
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Treadwell Therapeutics Engages Genezen to Advance its T Cell Receptor-Based Cell Therapy Pipeline

Treadwell Therapeutics, a clinical stage, multi-modality biotechnology company developing novel therapeutics for highly aggressive cancers, and Genezen, a cell and gene therapy Contract Development and Manufacturing Organisation (CDMO) have confirmed a partnership agreement to accelerate the production of T cell receptor (TCR)-based candidates to address unmet needs in cancer patients.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement